Enliven Therapeutics Q2 2024 Earnings Report
Key Takeaways
Enliven Therapeutics reported its second quarter financial results, highlighting the dosing of the first patient in the Phase 1b arm of the ELVN-001 clinical trial and the first patient in the Phase 1a clinical trial of ELVN-002. The company's cash, cash equivalents, and marketable securities totaled $312.4 million, expected to provide cash runway into late 2026.
Dosed the first patient in the Phase 1b arm of the clinical trial evaluating ELVN-001 in patients with CML.
Dosed the first patient in the Phase 1a clinical trial evaluating ELVN-002 in combination with trastuzumab +/- chemotherapeutic agents in HER2+ MBC and CRC.
Announced positive proof of concept data from the Phase 1a clinical trial in April.
Cash, cash equivalents and marketable securities totaled $312.4 million, which is expected to provide cash runway into late 2026.
Enliven Therapeutics
Enliven Therapeutics
Forward Guidance
The company expects to provide additional Phase 1 data in 2025, including data from approximately 60-100 patients across various lines of therapy with significant follow-up. Phase 1 monotherapy data and initial Phase 1a combination data are expected in 2025.